Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Saba H, Klein C, Mehta P, Hayes T, Roodman D, Lichtenstein A. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood 2010, 116: 3061. DOI: 10.1182/blood.v116.21.3061.3061.Peer-Reviewed Original ResearchEntity's Board of DirectorsGrade 1 neuropathyMultiple myeloma patientsSignificant co-morbiditiesOverall response rateCo-morbiditiesMyeloma patientsNewly-diagnosed multiple myeloma patientsNewly diagnosed multiple myeloma patientsEvaluate overall response rateAutologous stem cell transplantationElevation of serum creatinineResponse rateGrade 3 neuropathyRegimen of bortezomibDose of bortezomibAssociated with side effectsStem cell transplantationImproved toxicity profileProportion of patientsOlder patient populationHistory of cancerAdvisory CommitteeWeekly bortezomibBortezomib dose